UM  > Faculty of Health Sciences
Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials
Zheng, Wei1; Cai, Dong-Bin2; Yang, Xin-Hu1; Li, Lu1; Zhang, Qing-E.3; Ng, Chee H.4; Ungvari, Gabor S.5; Li, Xian-Bin3; Ning, Yu-Ping1; Xiang, Yu-Tao6
2018-08
Source PublicationJOURNAL OF PSYCHIATRIC RESEARCH
ISSN0022-3956
Volume103Pages:244-251
Abstract

Background:Lurasidone, an azapirone derivative, is a novel second generation antipsychotic with potent bindingaffinity for dopamine D2, serotonin 5-HT2A, 5-HT7,5-HT1A,and noradrenaline alpha2Creceptors. This updatedmeta-analysis of randomized controlled trials (RCTs) examined the short-term efficacy and tolerability of lur-asidone in the treatment of acute schizophrenia.Methods:Double-blinded RCTs reporting on the short-term effects of lurasidone were included. Standardizedmean difference (SMD) with their 95% confidence interval (CI), and number needed to harm (NNH) werecomputed.Results:The meta-analysis had 8 RCTs with 16 active arms that included 2373 patients with acute schizophreniawho were randomized to either lurasidone (20–160 mg/day; n = 1570) or placebo (n = 803) groups. Lurasidonewas superior to placebo with regard to change in total psychopathology [SMD: -0.34, (95%CI: -0.48, -0.20),P < 0.00001], positive symptoms [SMD: -0.47, (95%CI: -0.57, -0.36), P < 0.00001], negative symptoms [SMD:-0.34, (95%CI: -0.45, -0.22), P < 0.00001], and general psychopathology [SMD: -0.36, (95%CI: -0.48, -0.24),P < 0.00001]. Results were consistent for total psychopathology in 11 out of the 13 subgroups. Lurasidoneresulted in higher weight gain [SMD: 0.15, (95% CI: 0.06, 0.24), P = 0.001] and BMI [SMD: 0.17, (95%CI: 0.07,0.28), P = 0.002] than placebo, but the differences were not clinically significant. Lurasidone group had lessfrequent inefficacy (NNH = 14) and discontinuation due to any reason (NNH = 17), but was associated withmore frequent vomiting, akathisia, dystonia, parkinsonism, somnolence, dizziness, sedation, nausea, and weightgain of≥7% of the initial weight (NNH = 11–50).Conclusion:This meta-analysis of 8 short-term studies supported the efficacy and safety of lurasidone in theacute phase of schizophrenia, particularly at the higher dose range of 80 mg/day.

KeywordAntipsychotic Lurasidone Meta-analysis Schizophrenia
DOI10.1016/j.jpsychires.2018.06.005
URLView the original
Indexed BySCIE ; SSCI
Language英語English
WOS Research AreaPsychiatry
WOS SubjectPsychiatry
WOS IDWOS:000438004900033
PublisherPERGAMON-ELSEVIER SCIENCE LTD
The Source to ArticleWOS
Fulltext Access
Citation statistics
Cited Times [WOS]:9   [WOS Record]     [Related Records in WOS]
Document TypeJournal article
CollectionFaculty of Health Sciences
Corresponding AuthorNing, Yu-Ping; Xiang, Yu-Tao
Affiliation1.The Affiliated Brain Hospital of Guangzhou Medical University (Guangzhou Huiai Hospital), Guangzhou, China
2.Clinics of Chinese Medicine, The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, China
3.The National Clinical Research Center for Mental Disorders & Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China
4.Department of Psychiatry, University of Melbourne, Melbourne, Victoria, Australia
5.The University of Notre Dame Australia / Graylands Hospital, Perth, Australia
6.Unit of Psychiatry, Faculty of Health Sciences, University of Macau, SAR, Macau, China
Corresponding Author AffilicationFaculty of Health Sciences
Recommended Citation
GB/T 7714
Zheng, Wei,Cai, Dong-Bin,Yang, Xin-Hu,et al. Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials[J]. JOURNAL OF PSYCHIATRIC RESEARCH,2018,103:244-251.
APA Zheng, Wei,Cai, Dong-Bin,Yang, Xin-Hu,Li, Lu,Zhang, Qing-E.,Ng, Chee H.,Ungvari, Gabor S.,Li, Xian-Bin,Ning, Yu-Ping,&Xiang, Yu-Tao.(2018).Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials.JOURNAL OF PSYCHIATRIC RESEARCH,103,244-251.
MLA Zheng, Wei,et al."Short-term efficacy and tolerability of lurasidone in the treatment of acute schizophrenia: A meta-analysis of randomized controlled trials".JOURNAL OF PSYCHIATRIC RESEARCH 103(2018):244-251.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Zheng, Wei]'s Articles
[Cai, Dong-Bin]'s Articles
[Yang, Xin-Hu]'s Articles
Baidu academic
Similar articles in Baidu academic
[Zheng, Wei]'s Articles
[Cai, Dong-Bin]'s Articles
[Yang, Xin-Hu]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Zheng, Wei]'s Articles
[Cai, Dong-Bin]'s Articles
[Yang, Xin-Hu]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.